New combo therapy for pancreatic cancer shows promise in early safety trial
NCT ID NCT02021422
First seen Feb 23, 2026 · Last updated May 14, 2026 · Updated 11 times
Summary
This early-phase study tested whether adding the drug anakinra to standard chemotherapy is safe for people with advanced pancreatic cancer that has spread. Thirteen adults with metastatic pancreatic cancer took part. The main goal was to check for side effects, and researchers also looked at survival rates and immune system changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor Sammons Cancer Center
Dallas, Texas, 75246, United States
Conditions
Explore the condition pages connected to this study.